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This paper aims to provide evidence-based recommendations for health professionals, to develop a comprehensive cervical cancer
program for a clinic, a community, or a country. Ensuring access to healthcare is the responsibility of all societies, and the
Asia Oceania Research Organisation in Genital Infections and Neoplasia (AOGIN) is committed to working collaboratively with
governments and health professionals to facilitate prevention programs, to protect girls and women from cervical cancer, a disease
that globally affects 500,000 and kills nearly 300,000 women annually, just over half of whom are in the Asia Oceania region. We
share the vision that a comprehensive program of vaccination, screening, and treatment should be made accessible to all girls and
women in the world. The primary purpose of these guidelines is to provide information on scientific evidence on the different
modalities and approaches of cervical cancer prevention programs, for high resource and low resource settings. The secondary
purpose is to provide an overview of the current situation of cervical cancer control and prevention in various Asian Oceania
countries: their views of an ideal program, identified obstacles, and suggestions to overcome them are discussed.
1. AOGIN Consensus Statement on Prevention
and Control of Cervical Cancer
Cervical cancer can be prevented in two ways:
(i) primary prevention, aimed at preventing or neu-
tralizing the infection with human papillomavirus
(HPV), as for example through prophylactic HPV
vaccination, and
(ii) secondary prevention, aimed at preventing precan-
cerous lesions from progressing to invasive cancer
through screening, early detection, diagnosis, and
treatment, as clinically indicated.
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These are two distinct healthcare programs targeting women
of different age groups, namely, vaccination of adolescent
girls and young women, and commencement of screening
of women aged 25 to 35 years. These two programs can
be implemented in parallel or separately, depending on
availability of suitable infrastructure and resources. Ideally,
a combination of HPV vaccination programs together with
effective screening and treatment for precancerous lesions
has the greatest potential to significantly reduce the burden
of cervical cancer.
The Asia Oceania Research Organization in Genital
Infections and Neoplasia (AOGIN) endorses the World
Health Organization (WHO) position [1] on primary pre-
vention that “routine human papillomavirus (HPV) vacci-
nation should be included in national immunization pro-
grams.” The WHO statement is contingent on the provision
that:
(i) prevention of cervical cancer and other related HPV
diseases constitutes a public health priority,
(ii) vaccine introduction is programmatically feasible,
(iii) sustainable financing can be secured, and
(iv) cost-effectiveness of vaccine strategies in the coun-
try/region is considered.
As HPV vaccines are most efficacious in females who
are naı¨ve to vaccine-related HPV types, HPV vaccination
programs should initially prioritize high coverage in the
primary target population of girls aged 9-10 through 13
years.
AOGIN also endorses the principle that there should be
cervical cancer screening procedures available to all women
of appropriate age. This can be in the format of cervical
cytology, visual inspection with acetic acid (VIA) or Lugol’s
iodine (VILI), or an HPV (high risk) DNA or RNA screen
test.
2. Introduction and Background
Cervical cancer prevention and control is no longer just
a dream. With the introduction of prophylactic vaccines
against the oncogenic HPV 16 and HPV 18, with high cover-
age, we can prevent about 70% of cervical cancer worldwide
if administered prior to exposure to infection. We can also
expect the burden of cervical cancer to be greatly reduced
within a couple of decades. With respect to secondary
prevention, different screening methods, technologies, and
strategies are developing to meet the challenges of improving
their sensitivity, specificity, affordability, feasibility, accep-
tance, and compliance.
Each country in Asia Oceania has different burden
of cervical cancer, economic status, political background,
cultures, status of women’s rights, and resources available
for cervical cancer control. Thus, these guidelines serve two
purposes: the first is to provide information on the current
evidence on the different modalities and approaches, as well
as to reinforce the recently published FIGO Global Guidance
for Cervical Cancer Prevention and Control [2] with its
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Figure 1: Incidence and mortality rates (per 100,000 women)
due to cervical cancer (CC) in AOGIN country members (source
Globocan at http://www.iarc.fr/).
comprehensive and practical review, as a source of reference.
The second purpose is to provide contributions from various
Asia Oceania countries on their current situation on cervical
cancer control and prevention: what they consider as ideal
ways to do it, obstacles they face, and suggestions to
overcome them.
Although no country is the same, experience shows
that problems encountered could be quite similar, and it is
possible to learn from each other’s experience into finding
innovative solutions.
2.1. Epidemiology of Cervical Cancer. The incidence of
cervical cancer among Asia Oceania countries varies from
the lowest in Australia with age standardized rate (ASR) of
4.9 per 100,000 women to the higher ranges of 27 and 27.4
in India and Cambodia, respectively, to 28 in Mongolia, and
32 per 100,000 women in Nepal (Figure 1). Further, the ASR
may vary within a country, particularly in large countries
such as India and China. Moreover, if we consider analysis of
the time trends of disease incidence, studies have suggested
that cervical cancer incidence rates are increasing in recent
generations, such as in China [3].
2.2. Variations in Economy. The wealth of countries within
Asia Oceania varies widely not only among countries, but
within a country. The largest economies in Asia in terms
of nominal gross domestic product (GDP) [4] are Japan,
China, and South Korea. Still, within one country there are
also economic differences between urban and rural areas.
For instance, in China there are provinces with a very poor
economy, as compared to others. Similarly, in India, we see
affluent cities with strong economy beside more rural states
and poor provinces.
Journal of Cancer Epidemiology 3
2.3. Variety of Cultures. The countries of Asia Oceania
represent an aggregate of cultural heritage of many different
ethnicities, traditions, history, religions, and nationalities.
Hence, certain clinical practices common in one place may
not be acceptable in others. The social and moral norms
may differ and may vary within countries and communities:
hence the acceptance of specific clinical practices varies as
well.
2.4. Variation in Recognition of Women’s Rights. Women in
many parts of Asia Oceania have variable legal rights, and
some degree of discrimination against women is unfortu-
nately relatively common. Unless social, cultural, as well
as political will is coordinated to correct these inequalities,
health care to women may continue to be perceived as a low
priority, not just by providers and society but also by the
women themselves.
3. Primary Prevention Strategies
The goal of primary prevention is to avoid exposure to
the causative agent of diseases and thus to influence health
outcomes. Primary prevention of cervical cancer can be
achieved through prevention and control of genital HPV
infections that cause the cancer. HPV is a ubiquitous virus;
infections are very common and readily transmissible [5].
Health education campaigns geared at changing high risk
sexual behaviours and targeting all STIs of public health
significance, such as promoting delay in sexual debut and
decrease in the number of sexual partners (or in their
partners), as well as safe sexual practices can have some effect
in reducing or preventing genital HPV infections. However,
vaccination against HPV offers the greatest opportunity to
prevent these infections on a large scale. Two prophylactic
vaccines are now licensed and available to prevent HPV
infections.
3.1. Prophylactic Vaccines. Currently two cervical cancer
vaccines primarily aim for the prevention of HPV 16 and
HPV 18 infections, as these two viruses account for about
70% of cervical cancer cases consistently worldwide [6].
Both vaccines induce humoral and cellular immunity and
are designed for prophylactic use only, as they do not clear
existing HPV infections nor treat established HPV-related
diseases. Recently published studies report that these HPV
16/18 vaccines also induce antibody responses to, and show
partial efficacy against HPV types 31 and/or 45 [7, 8] which
are phylogenetically similar to HPV-16 and -18, respectively.
There are two key differences between the two available
vaccines: the bivalent vaccine protects against the oncogenic
types HPV 16 and HPV 18 while the quadrivalent vaccine
also protects against two nononcogenic HPV types (HPV 6
and HPV 11) that cause the majority of genital warts [9].
The bivalent vaccine contains a novel adjuvant ASO4 which
is considered responsible for a heighted immune response.
The age group for which the HPV vaccines are licensed
varies in different countries. The quadrivalent vaccine was
originally licensed for use in females 9 to 26 years old,
and has been extended in some countries up to 45 years
of age. In some countries it is also licensed for use in
males, including young boys. The bivalent vaccine is licensed
for administration to females aged 10 to 45 years old.
Recent data indicate sustained efficacy and immunogenicity
of the vaccines up to almost 9 years [10]. Extensive phase
3 clinical trials and postmarketing surveillance continue
to show that both HPV vaccines have high efficacy and
good safety profiles, similar to other commonly administered
vaccines. The characteristics, safety, immunogenicity and
efficacy profile, and target population for the two available
vaccines can also be found in the FIGO Global Guidance for
Cervical Cancer Prevention and Control [2] (FIGO guide),
Section 5.
3.2. Vaccination Programs. Merely the availability of effective
and safe vaccines is not enough if the vaccines cannot
be effectively delivered to target populations and with
high coverage. The strategies of vaccination in low and
high resource settings are discussed in the FIGO guidance,
Section 6 [2]. In this context, schools seem to be promising
venues for HPV immunization both in high- and low-
resource countries, though in the latter the high dropout
rates among girls may require additional strategies. It
is encouraging to note that, for example, HPV vaccine
coverage among school-aged female adolescents in Australia,
as well as in their catch up program up to 26 years of
age, has been estimated to reach up to 80%. This has
already translated into a statistically significant reduction
in new cases of genital warts in women under 27 years
of age in the order of 50%, with a herd immunity effect
on males [11]. Preliminary findings from demonstration
projects conducted by PATH in India, Peru, Uganda, Mexico,
and Vietnam suggest that a school-based approach can
achieve coverage rates similar to those found in Australia.
In Vietnam, community centre vaccine distribution had very
high rates of compliance in a PATH-initiated demonstration
project.
In Asia, the government of Bhutan has recently launched
a national cervical cancer vaccination program through
a collaboration with Merck Sharp & Dohme (MSD) and
the Australian Cervical Cancer Foundation (ACCF) [12].
Cervical cancer is the most common cancer among women
in Bhutan, with annual incidence rate (ASR) of 20.4 per
100.000 women. As part of the 6-year program, Merck
will provide quadrivalent (types 6, 11, 16 and 18) Gardasil
vaccine free to girls and young women in the country, in
the first year, and at a concessional price for the remaining
five years. Merck will also provide additional support for
implementation of the program. ACCF, a charity whose
mission is to minimize the incidence and burden of cervical
cancer and related women’s health issues on women, is
supporting the national vaccination program by providing
financial support to the Government of Bhutan to secure
doses of Gardasil at the access price after the first year of the
program is complete. The Royal Government of Bhutan is
committed to ensuring sustainability of this program beyond
the six-year partnership with Merck and ACCF. Bhutan is
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the first low-income country in the world to implement a
national vaccination program with an HPV cancer vaccine.
The Malaysian government has announced that it will
provide all 13-year-old girls with three doses of HPV
vaccine to prevent cervical cancer. The program may cost
the government RM150 million for 300,000 girls per year.
The program will most probably be conducted in schools
with the bivalent HPV vaccine (Cervarix) against HPV
types 16 and 18, the more common types of HPV amongst
Malaysian women. Pap smear tests will continue to be
provided every three years in this country in which incidence
of cervical cancer is 16.1 per 100,000 women, the second
most frequent cancer for women in Malaysia after breast
cancer. In Malaysia, women from the Chinese ethnic group
are at higher risk with incidence rate of 23.2 for every 100,000
women, compared to 16.4 in ethnic Indian women and 8.2 in
Malay women.
HPV vaccination has been named by the global alliance
for vaccines and immunisation (GAVI) as a priority vaccine
since 2008 which identified HPV vaccines as likely to have
the biggest impact on the disease burden in developing
countries. Both vaccines passed the WHO prequalification
process. Support will depend on GAVI raising additional
donor funds for countries wishing to introduce new vaccines
[13]. We await the success of this initiative.
Program planners in many other countries will need
to compare the costs of the two vaccines, depending on
negotiations with manufacturers, and determine which one
represents the better value based on available resources
and current health priorities. As with other new health
technologies, in many countries access to HPV vaccines
through private physicians and clinics is far outpacing public
sector programs. As a result, HPV vaccines are quickly
becoming available to girls whose parents have the financial
resources to cover the costs. However, this leaves the poor
with no cover. It will be important to undertake country-
specific assessments of technologies and cost-effectiveness
analyses, to make informed decisions about implementation
of cervical cancer prevention programs.
It is important to appreciate that although the combina-
tion of vaccination and screening programs should be the
aim for ideal cervical cancer prevention, countries lacking
the necessary infrastructure for effective screening, followup,
and treatment of women should feel encouraged to consider
HPV vaccination as a highly feasible, sustainable and cost-
effective tool to tackle the issue, particularly in protecting
younger generations, while building screening programs.
HPV vaccination is likely also to be beneficial to sexually
active women over 25 years of age, who are at continuous
risk of acquiring new HPV infections and developing cervical
intraepithelial neoplasia (CIN) and cervical cancer. Clinical
trial data show that both HPV vaccines are safe and
immunogenic in women up to the age of 55 years, and are
efficacious in women 24 to 45 years of age. The predicted
reduction in cost-effectiveness of vaccination with increasing
age, however, is likely to limit the implementation of routine
vaccination beyond the late 20s. The priority of routine
vaccination programs must be to target girls and young
women, complemented with catch-up programs extending
to ages 25-26 years, when resources allow. For sexually active
women over the age of 25-26, HPV vaccination can be
considered on an individual basis, as most women will have
the potential to benefit from vaccination [14]. In addition,
it has been shown that, in those who have been previously
infected with vaccine-related HPVs (antibody positive, DNA
negative to HPV 16 and/or 18), vaccinating these women has
reduced HPV 16- and or HPV 18-related lesions.
4. Secondary Prevention Strategies
Once initial HPV infection has occurred, the goal of
secondary prevention is to detect cervical disease in its
earliest stages in women with persistent infection, before
it progresses to invasive cancers. Since the 1950s, screening
for cervical cancer based on detection of abnormal cervical
cytology has been used worldwide. The impact of cervical
cytology can be seen in some countries with successful,
well-organised programs, with good coverage of the target
population, plus with high-quality laboratory assurance.
This is illustrated by the significant drop in incidence of
cervical cancer in Australia, in women of all ages, decreasing
from 12.7 to 4.9 per 100,000, with mortality decreasing
to 1.4/100,000, one of the lowest worldwide (see below,
Australia). However, examples of barriers to successful
implementation of cervical cancer screening programs in the
Asia Oceania region include lack of trained personnel for
sample collection, processing, and testing, lack of adequately
trained cytotechnicians, lack of high quality laboratory
infrastructure for screening tests, and lack of subsequent
follow-up colposcopy and treatment, due to both poor
compliance as well as lack of health care providers, and
not the least, the lack of awareness and support from
politicians and government for financing such programs.
Barriers encountered in low-resource settings can be found
in the FIGO guidance, Sections 8–11 [2]. Hence, alternative
methods for the secondary prevention of cervical cancer in
sexually active women, mostly over 30 years of age, have been
evaluated in numerous studies over the past 10–15 years in
different countries.
4.1. Screening Tests. Alternative screening methods have
been sought, reported, and used in low-resource settings.
These include visual inspection with acetic acid (VIA)
and Lugol’s iodine (VILI) and the single visit approach as
discussed in FIGO guidance, Sections 8-9 [2]. Traditionally,
a cervical smear is taken at the first visit and, if an
abnormality is found, the women must return for further
evaluation and at that point, diagnostic workup or treatment
will be scheduled as required. In contrast, in the single
visit approach, a screening test such as VIA provides rapid
results, and treatment, usually cryotherapy, is made available
to women with abnormal tests at the same visit, while a few
women who need further treatment are referred elsewhere as
appropriate. This approach is often referred to as the “Screen
and Treat” or “See and Treat” approach.
The procedure involves applying 3–5% freshly prepared
acetic acid to the cervix and observing after one minute.
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However, acetowhite staining is not specific for CIN, being
also able to stain mucosal ulceration due to other causes, for
example, herpes, and even immature squamous metaplasia
may appear acetowhite. Thus, up to 15–18% of women
in any population may screen positive, as the specificity
of VIA is lower than Pap. This leads to high referral
rates for further evaluation or to unnecessary treatment
of normal women in the single-visit approach. VIA results
are operator-dependent, hence subjective, with high inter-
observer variations, requiring proper quality control and
training-assessment protocols, as well as frequent retraining.
There are no uniform criteria for reporting VIA pos-
itivity, although there have been good efforts by IARC to
objectivise criteria and develop a training manual. Training
for VIA can be provided to nurses within about a week.
Training consists of a basic course on anatomy, equipment
requirements, and visual demonstration of normal and
abnormal cervix from slide sets, followed by hands-on
training.
Permanent records of VIA testing results cannot be kept,
in contrast to Pap slides that can be stored, or printouts of
HPV-reading equipments.
VIA is not suitable for postmenopausal women where the
squamocolumnar junction is not easily visible any longer and
has receded into the endocervical canal.
Evidence shows that providing a single VIA test followed
by cryotherapy treatment for test positive cases, can reduce
the lifetime risk of cervical cancer by 30%, in women between
the ages of 35 and 45 years. Cryotherapy treatment is less
suitable for women with high-grade lesions in whom the
cure rates range between 71% and 96% [15]. Other situations
not suitable for cryotherapy include large acetowhite areas,
extension into endocervical canal, lesion in vaginal fornix,
squamocolumnar junction not visualized, polyps, ulcers,
and distorted or atrophied cervix. If there is suspicion of
invasive cancer, biopsy and further evaluation is preferable
to cryotherapy.
Also side effects and complications are inherent to
cryotherapy: 4% women will have minor side effects (e.g.,
vaginal discharge, cervicitis, bleeding, abdominal cramps),
and 0.5% will have major complications (e.g., blood trans-
fusion, pelvic inflammatory disease). After cryotherapy,
women must abstain from sexual intercourse for a month,
or at least use condoms. Doing so might prove difficult in
some communities where women are often disempowered
and men may be reluctant to comply.
HPV testing for detection of high risk HPV in cervical
cells can increase the sensitivity for underlying lesions,
though with a decrease in specificity (as it may pick up
infection prior to development of lesions) as compared to
cytology. More and more data support using primary HPV
DNA testing combined with cytology, VIA, or other screen-
ing method for triage of women screened HPV-positive. The
role of HPV testing as an adjunct to cytology-based screening
and as a primary screening test is discussed in FIGO
guidance, Section 11 [2]. There are several diagnostic tests
for detection of oncogenic genotypes of HPV; some detect
HPV-DNA, and others target HPV-RNA. Recent research
indicates that HPV testing is the most sensitive screening tool
available at this time for the detection of underlying CIN 3
and cervical cancer. In 2009, a randomized controlled trial of
over 130,000 women in India showed that a single round of
HPV DNA testing by the Hybrid Capture 2 method reduced
cervical cancer deaths by about 50% within the eight years of
followup [16]. The HPV test is highly sensitive, although less
specific, in primary screening of precancerous lesions of the
cervix (CIN 2 and CIN 3). Globally there is high prevalence
of HPV in young women, declining in older women, as most
have cleared HPV infection by their early 30s. Therefore,
focusing HPV testing on women over the age of 30 years is
likely to yield the best results.
HPV testing does not have a role for triaging women
with clear cytological abnormalities (LSIL or HSIL), since
a considerable percentage of these women are HPV infected;
adding HPV testing would only add additional cost. But
there is significant benefit in using HPV testing to triage
women with undetermined cytological changes (ASCUS).
The combination of HPV testing and cytology has demon-
strated a slight increase in sensitivity for detection of CIN 2/3
compared to HPV testing alone, but this benefit will vanish
in areas where cervical cytology performance is suboptimal.
HPV screening has also been proposed when VIA is used as
a triage tool for women with a positive HPV result.
Currently, one of the factors of HPV testing is the high
cost. However, an affordable, rapid, and simple test has been
developed and is undergoing field trials [17]. Thus, even in
low-resource settings, it is expected that HPV testing can be
considered in the very near future.
4.2. Diagnosis. The screening test is only the first step of
a successful screening program. The followup of women
with positive results, monitoring women with abnormal
or undefined results, colposcopy and taking biopsies for
histopathology, and treatment of abnormal lesions are
necessary additional steps before any impact of the screening
program on disease burden can be achieved. The cost of all
these components may be prohibitive in some settings. In
addition, screening has challenges such as the complexity
of coordinating the several steps of the process, engaging
qualified health workers, and providing quality control tools.
In the case of cytology screening, colposcopy is essential
in making a final diagnosis on the severity of lesions
before deciding on treatment. Although colposcopy is not
a sufficient tool for screening, as alone it has low sensitivity
and low positive predictive value, it is essential in a cervical
cytology screening program, to guide the clinician to the area
most abnormal for biopsy for histology in order to make a
diagnosis of preinvasive or invasive cervical neoplasia.
In screening programs in high-resource settings, col-
poscopy remains the reference for making the diagnosis, as
histological assessment of biopsies taken from acetowhite
lesions or other abnormal areas is needed to make a definitive
diagnosis following abnormal cytology or any other abnor-
mal test. The indication for colposcopy varies depending on
the screening methods used (Refer to the FIGO guidance
for more details [2]). Colposcopy is usually carried out in
an outpatient setting. It has many fallacies: requires training
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and quality assurance and hence accreditation systems are
recommended and common in many countries.
4.3. Preventive Treatment Modalities. High-grade cervical
intraepithelial neoplasia lesions (CIN 2+) need to be treated
by excision to prevent potential progression to cancer.
Although ablative methods such as cryotherapy could be
a treatment choice for small, completely visualised lesions,
excisional methods such as loop electrosurgical excision
procedure (LEEP) or conization allow histological diagnosis
and assessment of margins to ensure complete removal
especially in larger lesions. The advantages and disad-
vantages of various methods, special considerations and
recommendations, and other issues are further discussed in
Sections 13-14 of the FIGO guidance [2]. For instance, there
are multiple management options for ablation of cervical
dysplasia. Cryotherapy has been in use for over 40 years as
a safe and effective way of destroying (ablating) CIN lesions
on the ectocervix, by freezing the cervical epithelial tissue.
Cells rapidly reduced to −20 degrees Celsius for three to
five minutes will undergo cryonecrosis. Cryotherapy is well
suited for low-resource settings. A review of the literature
shows a cure rate of 90% at one-year, and over 85% of women
found the procedure to be safe and highly acceptable [18].
Cervical cone techniques currently used include cold knife
conization (CKC), loop electrosurgical excision procedures
(LEEP/LLETZ), and laser conization. All three techniques are
effective in the treatment of CIN and studies have found no
difference in the sample adequacy between the techniques
[19]. No matter what the choice of treatment is, accessibility
and quality assurance should be ensured, as well as ongoing
monitoring and supervision of provider skills.
5. Treatment of Invasive Cancer or
Tertiary Prevention
For those women where screening detects invasive cervi-
cal cancer, available standard-of-care treatment should be
offered in order to achieve the goal of controlling the
spread of cervical cancer. Depending on the stage of invasive
cancer, the treatment choice may be surgery, usually radical
hysterectomy, with pelvic lymphadenectomy, radiotherapy,
or concurrent chemoradiation. Treatment of invasive cer-
vical cancer requires multidisciplinary contributions from
gynaecological oncologists, radiation oncologists, medical
oncologists, radiologists, and nurse specialists. Establish-
ment of a regional treatment centre with appropriately
trained specialists could be a challenge in low-resource
settings, and in rural areas. FIGO guidance, Section 17 [2],
provides information on advancements in this area and
recommendations regarding optimal therapy choices.
6. Special Considerations in
Low-Resource Settings
6.1. Primary Prevention. The vast majority of AOGIN mem-
ber countries or regions consider that HPV vaccination to
teenagers before sexual exposure should be implemented at
large, in accordance with the WHO position and recommen-
dations.
The obstacle to low-resource countries is mainly the
lack of national support in terms of financial resources and
infrastructure to ensure large coverage adolescent vaccina-
tion programs are instituted. Among the various vaccination
programs implemented so far, the strategy of delivering
HPV vaccines to school girls, 11–13 years, has shown
good coverage rates [20, 21]. Combining HPV vaccination
with delivery of other health interventions or education to
adolescent girls, such as vitamin A, iron supply or HIV pre-
ventive education, or tetanus toxoid immunisation (TT) or
meningitis vaccination may increase the cost-benefit of such
programs. Public awareness and health workers’ education is
needed for compliance and full implementation of effective
vaccination. The way forward for health professionals is to
educate the women, maintain an open dialogue with local
health authorities, and inform them about the benefits of
preventive interventions, while continuing to advocate for
financial support from national health ministries, as well as
to seek support from international procurement and health
agencies such as GAVI, UNICEF, WHO, and The Global
Fund.
6.2. Secondary Prevention. The vast majority of AOGIN
member countries consider that cervical cancer screening
should be offered to target populations, namely sexually
active women, particularly over 30 years of age. The choice
of different screening methodologies and strategies, for
example, VIA, VILI, rapid affordable HPV test, or cytology,
should be carefully considered based on accurate assessments
of the sensitivity, specificity, diagnostic values, time to deliver
results, coverage, follow-up rates, and cost-effectiveness
analyses.
When planning screening programs, six key elements
should be considered in order to ensure success, as listed
in Table 1. The choice of the screening method is the first
step, and should be based on local data of sensitivity and
specificity of each method, as these can vary depending on
the prevalence of HPV in the population.
For low-resource settings, the simplest method is
VIA/VILI or, in the future, HPV detection using a low-cost
test. It is desirable to use an adjunct method to confirm
screening results using cytology, colposcopy, or cervicog-
raphy and biopsy, before referring women to treatment,
although “screen and treat” should be considered, depending
on disease prevalence, infrastructure for delivery of services,
rates of compliance to followup, and resources. At least
cryotherapy should be available to treat identified high-grade
lesions, and surgery to remove invasive cancers. Screening
should start at age 30 or 35 years, depending on local data
on HPV prevalence and incidence of cervical neoplasia,
as well as resources. Screening should be offered to all
women at least once in their lifetime, but preferably every 5
years, if using VIA, or every 10 years if using HPV testing.
National cancer registries should be in place to be able to
measure disease burden and the advancement and success of
prevention programs.
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Table 1: Key elements to be considered in choosing a screening
strategy for low-resources settings.
Screening method
VIA/VILI or HPV DNA detection (low
cost)
Adjunct
Cytology or cervicography or colposcopy
with biopsy
Support
Treatment for CIN 2+ for example
cryotherapy, cold coagulation; and
treatment for cancer such as surgery and
radiotherapy
Age Starting at 30–35 years
Interval Once in a lifetime or every 5–10 years
Cancer registry National level coordination
Importantly, at least once or twice in a lifetime screening
is strongly recommended to be considered based on indi-
vidual countries’ preferences and availability of resources.
Similar to vaccination, public awareness and health workers’
education is needed for full implementation, to ensure
compliance and a successful program.
7. Special Considerations in
High-Resource Settings
7.1. Primary Prevention. The aim is to provide HPV vac-
cination to target populations. Among AOGIN member
countries, Australia and New Zealand so far were the first to
offer HPV vaccination to target populations (12 year old, and
in the first two years of the program catch up to 26 years old)
supported by the government [22]. Recently, the Malaysian
government has intended for vaccination and will be offering
a government-funded program. Though both HPV vaccines
have been licensed and registered for use in other AOGIN
member countries, they are currently administered based on
self-financing and in an opportunistic manner.
The way forward is to continue to inform governmental
authorities about the disease burden and potential benefits
and to advocate for political support to adopt HPV vac-
cination, as part of national immunization programs. In
addition, education of health workers and of the public at
large is needed for full implementation and high compliance.
The modalities of pricing and reimbursement depend
on local health systems and local legislation and policies,
as well as negotiations between governments and health
insurers. Some countries have also created reimbursement
mechanisms such as those based on centralized government
procurement and distribution for negotiated lower prices,
but administered by private practitioners. Other countries
provide reimbursement of the vaccination course, after
purchase by the patients and proof of administration of the
three required doses by a practitioner.
7.2. Secondary Prevention. The aim is to provide cervical
cancer screening to target populations.
Many AOGIN member countries have been using cer-
vical cytology screening with a variety of programs and,
Table 2: Key elements to be considered in choosing a screening
strategy for high-resources settings.
Screening method Cervical cytology or HPV DNA testing
Adjunct
HPV testing and colposcopy for
abnormal cytology, colposcopy, and/or
biopsy for those persistently HPV
DNA(+)
Support
Colposcopy and treatment for CIN2+
and cancer
Age
Starting at 25 to 30 years old and ending
at 65 years old
Interval Once every 3 to 5 years
Screening Registry Available
Cancer Registry
National, regional, and local level
available
indeed, decrease in incidence and mortality from cervical
cancer was demonstrated, for example, in Australia and in
Taiwan.
While the provision of screening is essential to allow
reduction in disease burden, having registries for cytology
and cancer are important elements to help in monitoring the
success of programs. Furthermore, financial and government
support is essential for a successful population-based screen-
ing program.
In the United States for example, cytology screening with
HPV testing as an adjunct is recommended for women over
30 years of age, and at intervals of three years upon negative
results. Screening using high-risk HPV testing shows higher
sensitivity, though lower specificity, and this method is being
explored as a primary screening tool in a number of research
settings. Algorithms in using HPV testing with or without
cytology are yet to be agreed upon in Asian countries.
The use of cytology screening followed by HPV testing, or
HPV testing followed by cytology for confirmation, is likely
to be used, rather than VIA or VILI. For definitive diag-
nosis of lesions, colposcopy and histopathology should be
encouraged. Treatment modalities in high-resource settings
should be based on LEEP/LLETZ or conization, rather than
on cryotherapy. Surgical and radiotherapy treatments are
available in most high-resource settings. Cancer registries
have shown their utility in monitoring disease burden and
success of prevention programs. In some high-resource
settings, screening registries are also available and allow
call-recall mechanisms and follow-up procedures, facilitating
quality assurance schemes and providing good quality data
and corrective actions to improve the effectiveness of the
programs. The key elements to be considered in choosing
a screening strategy for high-resources settings are summa-
rized in Table 2.
Public awareness and health workers’ education and
training will be essential, especially if HPV testing is to be
used for screening. The potential stigma associated with
genital HPV infection could lead to resentment and guilt
feelings among those who screen positive for HPV.
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8. Special Considerations and
Recommendations
8.1. AOGIN Recommendations for Screening Programs in Low-
Resource Settings. Affordable, effective strategies have been
proposed that could work in low-resource settings.
8.1.1. Visual Inspection Techniques. These include visual
inspection with acetic acid (VIA) and visual inspection with
Lugol’s iodine (VILI). These tests are suitable for women of
the reproductive age group 30–50 years, but not after the
menopause, since the squamous junction recedes into the
ectocervical canal and the entire transformation zone is no
longer visualised (Figure 2). The advantages of VIA/VILI are
(i) simple, inexpensive, minimally reliant upon infras-
tructure,
(ii) easy to learn, can be performed by many levels of
health care providers (including nurses and mid-
wives) after short training, may be integrated into
primary health centre services, and
(iii) results are available immediately, thus can be inte-
grated into screen and treat strategy.
The sensitivity of VIA ranges between 66% and 96%,
with specificity between 64% and 98% [23]. Low-level
magnification (VIAM) did not improve the test performance
[24]. Addition of VILI has been shown to improve the
sensitivity and specificity of VIA [25]. Health workers find
the colour gradients of VILI easier to define than VIA.
Detection rates of CIN 2/3 using VIA, VILI, and cytologic
findings of ASCUS and LSIL were 3.7, 3.3, 4.5, and 4.2 per
1000 women, respectively [26].
8.1.2. HPV Testing as “Single Round of Screening”. In a
low-resource setting, it is difficult to ensure screening at
regular intervals. Sankaranarayanan and collaborators have
shown that in a low-resource setting in rural India, a single
round of high-risk HPV DNA testing by Hybrid Capture 2
technique reduced the rate of advanced cervical cancers and
associated deaths by 50%, as compared with the unscreened
control group over 8 years followup. Also, a single round
of cytologic-testing or VIA in a similar setting was not
associated with such a significant reduction in advanced
cervical cancer and related death rates. The age-standardized
rate of invasive cancer among screen-negative women was
almost four times lower in HPV-negative women compared
to cytology-negative and VIA-negative women, indicating
that a single negative HPV DNA test had a higher negative
predictive value than the other methods [16].
HPV testing is sensitive, objective, reproducible, and can
even be performed by a technician. Presently the drawback
is that HPV testing is expensive. A rapid affordable test
(careHPVTM, Qiagen Inc.) is expected to become available by
2011-2 [17]. Thus, implementation of a nationwide program
of once in a lifetime testing around age 40 years with low-
cost HPV testing holds significant promise for rapidly and
substantially reducing the cervical cancer burden (Figure 3).
8.1.3. Screen and Treat Modalities. The single visit approach
ensures high compliance and reduces wastage of limited
resources in screening women who will not return for
management of an abnormal screening test. The best age for
a once in a lifetime screening is between 35 and 40 years.
Visual inspection and treatment by cryotherapy at the
same visit for ectocervical lesions that can be covered by
a cryoprobe was found to be safe, acceptable, and feasible
[27]. This screen-and-treat method effectively cured CIN
in 88% women, including 70% women with a baseline
diagnosis of CIN 3 [28]. A randomized trial in Southern
India found a 25% reduction in cervical-cancer incidence
and a 35% reduction in mortality compared to controls,
with VIA followed by cryotherapy [29]. If facilities permit,
a biopsy should be taken prior to cryotherapy for post hoc
confirmation of diagnosis, if possible. Loop electrosurgical
excision (LEEP) is recommended for larger lesions.
Screen-and-treat strategies have also been tried with
cytology [30] with a rapid turnaround time for the reporting
of cytologic results and HPV testing [31]. These overcome
the problem of loss to followup but still present the problem
of infrastructure and cost.
8.2. AOGIN Recommendations for Screening Programs in
High-Resources Settings
8.2.1. HPV Testing. Persistent infection with high-risk HPV
types is a necessary cause of cervical cancer and high-risk
(hr) HPV testing as a screening test has 20–40% greater
sensitivity, but 5–10% lower specificity than a Pap smear
[32]. Women who were hrHPV DNA negative appear to be
at low risk for CIN 3+ for up to 10 years (high negative pre-
dictive value (NPV)) [33]. Liquid cytology with automated
reading may be also highly objective and reproducible for
high-resource settings. The NPV of being both cytologically
and hrHPV DNA negative is extremely high, over 99.9% in
most studies.
Switching from a cytology-based to an HPV-based
strategy will detect 120–300 extra cases of CIN 2+/100,000
women screened. Thus, a strong case should be made for
considering utilizing HPV DNA testing as the primary
screening test in women aged over 30 years [34] (Figure 4).
Five to 8% of women over 30 years of age will be high-risk
HPV positive. Cytology may be used to triage HPV-positive
women into 2 groups: those requiring colposcopy and those
who can be followedup (Figure 5). The higher specificity
of cytology makes it ideally suited to rule out high-grade
lesions/invasive cancer in HPV positive women.
HPV DNA-positive, cytology-negative women should be
retested in 12 months with both cytology & HPV DNA
testing: there is no immediate necessity for colposcopy.
Persistent HPV infection does require colposcopy. Four-
quadrant biopsies, plus endocervical curettage, has been
recommended even if there is no obvious lesion on cytology
in these cases [35].
For women who are both cytology and HPV negative, the
screening interval may be safely increased to 8 or 10 years
[36–38].
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Figure 3: Schema for low-resource situations, starting with afford-
able HPV testing.
Some of the strategies that can be incorporated in an
HPV-based screening program in high resource settings
include the following.
(a) “Reflex” cytology: A specimen is obtained from all
women using a liquid collection media suitable for
both HPV DNA testing and cytology. Specimen is
initially tested for high-risk HPV, but processed for
cytology only if HPV positive. This approach would
eliminate the need for cytology in 90% to 95% of
women, and will depend on the availability or not of
cytotechnicians in the setting.
(b) HPV genotyping: Women with persistently positive
specific high-risk types of HPV (types 16, 18, 33, 45,
or 31) are at higher risk for having underlying or
subsequent CIN2+ (referred for colposcopy), while
those with other hrHPV types are at a lesser risk
(repeat HPV test in 12 months) ultimately for can-
cer cervix. Commercially available HPV genotyping
assays to identify the specific type of HPV are now
being considered for introduction for clinical use
[39]. Whilst there are some guidelines for testing
with high-risk HPV DNA assays, there are no formal
guidelines yet for genotype-specific assays.
(c) “Reflex” cytology + HPV genotyping: The third option
is to screen using hrHPV testing and then use
a combination of both reflex cytology and HPV
genotyping to identify which HPV DNA-positive
women need colposcopy. This may be justified only
in settings where access to colposcopy is limited
and high cost. Cost-effectiveness analysis may be
conducted before establishing the strategy.
8.2.2. Cytology as Primary Screening. This is recommended
for screening women over 30, and also in women under 30
years who have been sexually active for over 3 years. Liquid-
based cytology has some advantage of improved sensitivity
and fewer unsatisfactory results compared to conventional
cytology by Pap.
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8.3. Special Considerations for HPV Vaccination Programs
8.3.1. HPV Vaccine Efficacy and Safety. The HPV L1 VLP
vaccines are safe and well tolerated. They are highly immuno-
genic. These vaccines are essentially empty protein shells that
consist of virus-like particles (VLP) and do not contain viral
DNA; so these vaccines are not infectious and nononcogenic.
Phase 3 clinical trials have documented the safety, efficacy,
and immunogenicity of the quadrivalent and bivalent HPV
L1 virus-like particle vaccines in preventing vaccine-related
HPV high-grade dysplasia in those initially naive to HPV
16 and/or 18. These data have been presented to regulatory
authorities in over 100 countries around the world who
have provided approval for marketing of the products for
use in target populations. High sustained efficacy of the
prophylactic vaccines up to 5 and 8.5 years of followup have
been reported [10, 40, 41].
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The bivalent HPV vaccine protects against the two
major cancer causing HPV viral types 16 and 18, and
the quadrivalent HPV vaccine protects against four viral
types 6, 11, 16, and 18, thus making it effective for
prevention of cervical cancer, as well as for vulvar and
vaginal warts. Both these vaccines translate into protection
of cervical cancer in the order of 70–75%, which represents
the percentage of invasive cancers attributable to HPV-16
and -18. Both vaccines have demonstrated greater than
93% efficacy in preventing HPV-related high-grade cervical
neoplasia (CIN2+). In addition, the quadrivalent vaccine
has been shown to be 100% efficacious in preventing vulvar
intraepithelial neoplasia (VIN) and vaginal intraepithelial
neoplasia (VanIN2+) [42], and showed 100% efficacy in
preventing genital warts.
Noteworthy, they also showed efficacy against CIN2+
caused by other oncogenic HPV types, phylogenetically
related to HPVs 16 and 18. For instance, the bivalent
and the quadrivalent vaccines showed, respectively, 68%
and 33% efficacy against lesions specific to HPV types
31/33/35/39/45/51/52/56/58/59 [43].
Adverse events associated with the HPV vaccines are
much the same as with other vaccines, such as hepatitis
B vaccines, with respect to fatigue, headache, myalgia,
gastrointestinal complaints, arthralgia, elevated temperature,
rash, or urticaria. Fainting after HPV vaccination was found
to be more common among teens than among young
children or adults [44]. However, fainting among teens is
most often a response to the injection process rather than a
side effect of the vaccine. A study in the United States showed
that fainting was not more common after HPV vaccination
compared to other vaccines given to teenagers and young
women. Therefore, as with other vaccines, a standard fifteen-
minute resting period is recommended postvaccination to
prevent any injury associated with fainting [45].
Events involving hospitalization, death, disability, life-
threatening illness, or other medically important conditions
account for approximately 3 per 100,000 events reported to
the US Vaccine Adverse Events Report System (VAERS) in
the US. There does not appear to be any significant difference
in the number or severity of adverse events between the two
HPV vaccines [46].
Other potential vaccine-related adverse effects include
Guillain Barre Syndrome (GBS), venous thromboembolic
events (VTEs), and serious allergic reactions. However, when
reviewing the background rate of these events within the
age-matched general population, HPV vaccines have not
been shown to increase risk of these events among women
with any known risk factors. The relative risk of venous
thromboembolic events (VTEs) such as deep vein blood clots
is 2 per 1,000,000 individuals vaccinated with Gardasil in
the US. Ninety percent of cases (28 of 31 VAERS reports,
all in women ages 15–39) had a known risk factor for VTEs
including use of oral contraceptives and family history [47].
8.3.2. Recommended Immunisation in Low-Resource Settings.
The ideal age for the administration of the HPV vaccines is
between 10 and 13 years, and an effective way to deliver them
while maximizing compliance to the three doses is in school-
based vaccination campaigns or programs, where delivery is
also likely to be cost-effective. As previously mentioned, a
standard fifteen-minute resting period is recommended for
adolescent postvaccination to prevent any injury associated
with fainting. Moreover, ensuring that the individual girl
who has been vaccinated is not within view of others about
to be vaccinated is helpful. The vaccines are available in a
single-dose (0.5 mL) vial or prefilled syringe; no dilution
or reconstitution is required. The vaccine is administered
intramuscularly as three 0.5-mL doses, injected into the
deltoid region of the upper arm. Vaccination of males
in the context of large scale public vaccination programs
or campaigns is not recommended, as the potential cost-
effectiveness, cost-benefits, and herd immunity effects have
not yet been fully demonstrated. However, in considering
equity and prevention of other HPV-related diseases in
males, as well as herd immunity, should uptake in women
be reduced, vaccination of males may well be appropriate.
8.3.3. Recommended Immunisation in High-Resource Settings.
In Western Europe, for example, where healthcare budgets
and existing infrastructure can more easily accommodate
the introduction of new vaccines, nine countries (Denmark,
Germany, Greece, Italy, Luxembourg, Netherlands, Portugal,
Spain, and the UK) offer HPV vaccination free of charge
to at least one age-cohort of females, and additional 3
countries (Belgium, France, and Sweden) offer HPV vacci-
nation on a copayment basis. Australia is the first country
to implement a comprehensive school-based government-
funded schoolgirl vaccination, while in western Europe, the
UK and Switzerland have implemented a nationwide school
based vaccination program, while in Spain only 9 of the 19
autonomous regions currently deliver HPV vaccines through
this mechanism. School-based vaccination programs are
known to achieve high coverage of the target population for
paediatric and adolescent vaccines [48] while on-demand
provision through healthcare providers, even if supported by
direct invitation and/or public education programs, usually
has suboptimal coverage rates and can lead to missing lower
socioeconomic groups and minorities.
In high-resource settings, HPV vaccination of girls is
recommended for girls around 12 years old, and in addition
catch up vaccination for girls up to 15–18 or even extended
up to 26 years of age, depending on the country resources and
decisions, as extended catch up could accelerate the impact of
vaccination on reduction of cervical cancer incidence [49].
8.3.4. Vaccination of Mid-Adult Women. While the priority
of vaccination programs is to target young girls and women,
benefits of vaccination continue even in older women as
there is a continuing risk of new HPV infections throughout
life, and infections acquired in later life are more likely to
be persistent. For sexually active women over the age of 25
years, vaccination can be considered on an individual basis
as most will have the potential to benefit from vaccination.
Evidence from clinical trials suggests benefit to women aged
18–25 years similar to the 15–17 years age group. There is
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no recommendation for HPV testing as a prerequisite to
vaccination as it is unlikely that women would be positive
for all HPV types included in vaccines.
8.3.5. Postmarketing Surveillance. Surveillance needs to be
sensitive enough to document any unexpected adverse events
that occur after immunization, but also recognize that in
any population over a given period of time, such as a year,
new cases of diseases and health problems may arise in
its members. Whilst both the detection of adverse events
following immunization, and the subsequent requirement to
disentangle chance association from causality, are challenges
faced by any vaccination surveillance system, HPV vaccina-
tion programs potentially face a specific challenge in relation
to vaccine safety surveillance. This challenge relates to the
target group for vaccination comprising preadolescent and
adolescent girls and young women. Incident diseases in this
population group are different from those that occur with
the traditional infectious diseases framework of children, and
who are the usual target group for large scale vaccination
programs. Moreover, the time frame in which the disease
(cervical cancer) occurs is so much greater than traditional
infectious diseases.
Consequently, HPV vaccination surveillance systems will
need to be able to refer to background rates of diseases in
the target population to determine whether cases of new
onset disease reported after vaccination are occurring at a
greater than expected rate and, just as importantly, be able to
communicate about such occurrences and rapidly investigate
through data linkage studies if necessary. Not all countries
may be able to achieve this; it will require registries for HPV
vaccination and cervical cytology, as well as cancer registries,
and the ability to link them to changes in disease outcome.
As far as possible recording of routine adverse events
following immunization (AEFI) notifications and vaccine
safety assessments should be standardized in order to
improve accuracy and completeness of information about
adverse events both in pre- and postlicensure clinical studies
as well as in safety surveillance systems [50]. A summary
of reports to the vaccine adverse event reporting system
(VAERS) following receipt of quadrivalent HPV concluded
that most of the AEFI rates were not greater than the
background rates compared with other vaccines, but there
was disproportionate reporting of syncope and venous
thromboembolic events. The significance of these findings
must be tempered with the limitations of a passive reporting
system. In addition, an analysis of the HPV-16/18 bivalent
vaccine trials alone was also undertaken (N = 39, 160) and
demonstrated a low rate of autoimmune disorders, without
evidence of an increase in relative risk associated with AS04
adjuvanted vaccines [51].
Based on the official statements of national and inter-
national agencies and expert immunisation groups (WHO,
CDC, FDA, PHAC, ATAGI, EMEA, STIKO, PEI, AFSSAPS,
and others) to date, as well as a series of reports, HPV
vaccines seem to be safe and effective vaccines of great
importance for women’s health. However, it is vital that
continued and careful monitoring is undertaken so that
any rare but potentially important adverse events can be
detected, and verified, if and when they occur.
8.3.6. HPV Vaccines and Pricing. To date, the price of HPV
vaccines varies from country to country and dependent
on whether purchased in the context of private or public
vaccination. The available information on pricing in various
countries varies from over 200 US dollars per dose in
the private sector in Switzerland, 150 US dollars per dose
in Hong-Kong, 120 US dollars per dose in Australia and
Singapore, down to 30 US dollars per dose, in public
programs in the Philippines and reduced now to 40 US
dollars in India for example. Public nationwide programs
are likely to negotiate lower prices, than in the private sector
vaccination, and drive prices further down. In addition, for
resource-poor countries, the manufacturing pharmaceutical
companies have agreed to cost down price.
8.3.7. Screening after Vaccination. Screening has to continue
after vaccination as up to 30% of cervical cancers may not
be prevented by currently available vaccines, women may
have acquired infection prior to vaccination and there may
be some cases in spite of vaccination. At the present time,
there is no change in the screening recommendations, but
it is expected that with time there will be fewer cytological
abnormalities, which will lead to further lowering in the
accuracy of cytology and greater emphasis on HPV testing
as a screening method.
9. Contributions from Some Countries
within the AOGIN Region
It is important to share our experiences within the Asia
Oceania region, in order to facilitate the formulation of
national guidelines that suit the purpose of each country.
In the following section are contributions from AOGIN
member countries or regions sharing their experience on
cervical cancer control, namely from Australia, China, Hong-
Kong, India, Korea, The Philippines, Singapore, Taiwan, and
Thailand.
9.1. Australia
9.1.1. Current Situation in Cervical Cancer
Control and Prevention
(a) Primary Prevention: Prophylactic Vaccination. Australia
registered the quadrivalent vaccine in June 2006, the only one
registered at that time. In November that year, the Australian
government announced funding for an HPV vaccination
program which was initiated in April 2007, as a school-based,
ongoing program for 11- to 13-year-old girls [22].
In addition, for the first two years of the program, a
one-time funded catch-up vaccination opportunity phase
for those up to 26 years of age, began in July 2007 and ended
in December 2009. It was largely delivered in school-based
programs, and for women aged 18 to 26 years, through
general practice (GP) and community-based immunisation
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providers. The ongoing program for 11–13-year-olds is
now in its fourth year and is an ongoing, annual program
delivered in the first year of high school [22]. By the end of
2008, the bivalent vaccine had also been approved for use in
this program.
Australia is a world leader in the success of this HPV
vaccine program, as the well-organized program high
uptake, of nearly 80%, and with around 75–80% estimated
uptake in the catch-up program. By May 2009, over 5
million doses of the quadrivalent vaccine had already
been distributed in Australia. The program’s effectiveness
has already translated into a reduction in genital warts,
the first indicator of success of the program in a real
world setting. In a retrospective review of new cases of
genital warts being seen in the Melbourne Sexual Health
Clinic, since the introduction of the national program
for young women, irrespective of their vaccination status,
the proportion of women under 28 years with warts
diagnosed decreased by almost 50% (48% in 2008) but
not in women over 28 years of age. Of note, since 2008
there has been a significant decline in genital warts in
heterosexual men (17%), who did not receive vaccination,
suggesting a herd immunity effect of HPV
vaccination [12].
The next expected change that would be anticipated
would be in rates of abnormal Pap smears and we look
forward to review of this through the HPV vaccine register,
which is also part of the HPV vaccine program. This will
ultimately allow for measures of vaccine effectiveness in
reducing cervical cancer burden on a population basis, by
linkages of well-established cancer, Pap cytology, as well as
vaccine status.
(b) Secondary Prevention: Cervical Cytology Screening.
Australia has a very effective secondary prevention program
for cervical cancer, the National Cervical Screening Program
(NCSP). The program provides organized, cervical cytology
screening with high coverage, as well as high quality
laboratory assurance, in addition to adequate treatment
for precancerous lesions. The NCSP currently consists of
regular (2 yearly) Pap testing, targeting women aged 18 (or
2 years after sexual debut) to 69 years. The NCSP program
is well organized and commenced comprehensively in
1991. The success of this is exemplified by the significant
drop in incidence of cervical cancer in women of all ages
decreasing from 12.7 to 4.9 per 100,000, with mortality
decreasing to 1.4/100,000, one of the lowest worldwide [52].
Hence cervical cancer has now fallen to the eighteenth most
common cause of cancer death among Australian women in
general. Notwithstanding, the success of the NCSP, however,
are the higher incidence and mortality rates for cervical
cancer in indigenous women. Incidence and mortality rates
in indigenous Australian women approach those close to
developing countries with mortality rates in 2001 being
over four times greater than nonindigenous women, and
incidence rates 4 to 5-fold higher. This is largely because of
lack of ready access to services and resultant poor screening
services particularly in remote areas [53].
9.1.2. Challenges and Suggestions to Overcome Obstacles
(a) Vaccination of Males. Clinical phase 3 trial data in
males of 16–26 years for the quadrivalent vaccine show it is
well tolerated, induces a strong type-specific immunological
response comparable to that of females, and reduced vaccine
HPV-type-related genital infection, as well as disease, includ-
ing genital warts as well as anal intraepithelial neoplasia due
to vaccine related HPV types [54, 55].
Ultimately, comprehensive cost-benefit analyses are
needed to determine the efficacy of male as well as female
programs in the overall Australian population [56].
(b) Innovative Screening Strategies. With an increased vac-
cinated population of young women, the positive predictive
value (PPV) of Pap cytology will decrease. Hence the current
program is shortly to be reviewed and may result in changes
to the age of commencing screening as well as use of a
more sensitive assay such as HPV DNA and use of cytology
for triage. This will be reviewed as part of the Government
Renew Program shortly to commence.
(c) Education. Appropriate communication to the general
public about cervical cancer vaccines will vary between
cultures and countries. It was noted, for example, in an
Australian survey, that endorsement by the medical profes-
sion, and professional bodies influenced individual’s choice
on adoption of a vaccine program [57–59]. This was found
similarly for women in Singapore, and despite the general
lack of knowledge regarding HPV and the vaccine availability
among the general public [60]. Of note, Singaporean men
were found to have moderate knowledge of cervical cancer
but poor knowledge and awareness of HPV. Although these
men showed strong support for HPV vaccination, overall
findings highlight the importance of including men in
education campaigns that aim to decrease the incidence of
cervical and other HPV-related cancers and to increase the
uptake of HPV vaccination [61].
9.2. China
9.2.1. Current Situation in Cervical Cancer Control and
Prevention in Main China. In China, there is not yet a
nationwide program for cervical cancer prevention. Neither
of the HPV vaccines has been licensed yet in China. The
priority for cervical cancer control is secondary prevention
by using less expensive, easy to operate, and appropriate
screening technologies.
In recent years, China’s government has put the health
of rural women firmly on their agenda and is focusing its
efforts on secondary prevention of cervical cancer. Started
in 2006, two demonstration sites for the early detection and
treatment of cervical cancer have been established in rural
areas, as well as in urban areas for comparison, sponsored
by the Ministry of Health and the Cancer Foundation of
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China (CFC). At present, free cervical cancer screening
examinations by either Pap smear or VIA/VILI have been
available for women between 35 years and 59 years under
a government-sponsored program proposed by MOH and
the All-China Women’s Federation. It is expected that over
the next 3 years, 10 million women from rural areas in 221
counties will be able to access this service. It is a part of
the country’s ambitious 850 billion RMB (US$124 billion)
health reform plan. The plan will concentrate on China’s
less developed central and western regions, and cover broad
preventive and screening efforts, ranging from vaccination
drives to improved cooking and sanitation facilities in rural
areas.
9.2.2. Ideal Situation in Low- and High-Resource Settings.
Considering the large differences in the rates of cervical
cancer as well as the health and economic situation across
geographical areas of China, it would be reasonable to
develop ad hoc regionally tailored screening strategies that
best address specific needs of the different areas.
It is broadly accepted that well-organized cervical can-
cer prevention programs based on screening with cervical
cytology lead to impressive reductions in cervical cancer rates
in developed countries. However, it has not been possible
to transfer this expertise and successful experience to the
developing world, where the infrastructure for cytology-
based screening either does not exist or has been problematic.
While both the cytology test and HPV test are not widely
available for women in rural China, visual inspection with
5% acetic acid (VIA) and visual inspection with Lugol’s
iodine (VILI) reported acceptable values of sensitivity and
specificity for CIN2+ disease detection among Chinese
women [62, 63]. In addition, the costs of VIA/VILI imple-
mentation are low.
A newly developed HPV DNA test (careHPVTM) has been
shown to be a very promising option for cervical cancer
screening in China and other low- and middle- socioe-
conomic populations. The careHPVTM test is specifically
designed for screening women in low-resource regions of the
world, where diagnostic laboratory facilities are not available,
in order to identify individuals at high risk of developing
cervical cancer [17]. The test can detect the presence of
14 high-risk or potentially cancer-causing types of HPV.
The test also can be useful in other low-resource regions
of the world such as India, Africa, and Latin America.
The test is able to rapidly produce accurate results—
within 3 hours—thus eliminating the need for additional
patient visits to health clinics for further evaluation and
treatment. For instance, a woman found to have a high-risk
HPV infection can undergo further confirmatory diagnostic
testing immediately by colposcopy or VIA, and in certain
cases, get immediate treatment, if desired.
9.2.3. Challenges and Suggestions to Overcome Obstacles
(a) Education. China’s large population size (total popu-
lation of 1,337,411,000), along with its ongoing economic
and cultural metamorphosis, creates enormous challenges in
health care.
Cervical cancer is over-represented in rural areas—owing
to lack of education, poverty, and inability to pay for health
care. The ambitious government-sponsored program could
be a step towards provision of universal cervical cancer
screening nationwide, with an estimated 300 million eligible
women in China.
This is the first time that the Chinese government has
proposed to gradually widen access to public health services
so that women in rural China are included. To achieve high
coverage of screening it would be necessary, firstly, to inform
the female population through educational campaigns about
the disease and prevention programs; secondly, to ensure that
screened women would receive the results and confirmatory
diagnosis on the same day; thirdly, to validate the referral
system and treatment clinics, as well as the respective cancer
registries. However, the health service capability and the
public health challenges are substantial.
(b) Innovative Screening Strategies. The careHPVTM test is
promising as an affordable screening method for public
health cervical cancer prevention programs in low-resource
settings. We should develop and strengthen the partnerships
between NGOs, the public-sector, the private-sector, and
health care professional organizations. It is also imperative
that these programs address the needs of the poor and ensure
that all members of society benefit equally. Government, civil
society, and charities should be responsible for ensuring that
this objective is met.
9.3. Hong Kong
9.3.1. Current Situation in Cervical Cancer Control and
Prevention in Hong Kong. In 2006, cervical cancer was the
fifth most common female cancer in Hong Kong. According
to the Hong Kong Cancer Registry, there were 459 new cases
of cervical cancer, accounting for 4.2% of all new women
cancer cases. The median age at diagnosis was 54 years.
Meanwhile, cervical cancer was the eighth most common
cause of female cancer registered deaths in 2007. There were
129 female registered deaths due to this cancer, accounting
for 2.7% of female cancer registered deaths.
Both the bivalent and quadrivalent vaccines are available
in Hong Kong. There is however no national vaccination
program. The vaccines are widely available in most private
clinics and women health centres. There is wide media
coverage of both vaccines, but uptake statistics are lacking.
The vaccines are licensed for women between 9 and 26 years
old, but may be extended to cover older women in the near
future. A three-dose course costs about 3500 HKD (ca. 450
USD).
The Hong Kong department of health launched a cervical
screening program since 2004 and up till December 2008;
over 341 000 women had registered with this program. The
program mainly covers women between the ages of 25 and
64 and involves annual cervical smear for 2 years. If these
are normal, smears with 3 yearly intervals would be done
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until the age of 65 years. Cervical smears can also be done
for women over the age of 65 if they have never had a
smear done. With this screening program in place, in 2008,
about 63% of the target population had a cervical smear
done within 3 years. Apart from the department of health
clinics, women may also obtain smears from family planning
associations, various women health clinics, as well as private
family physicians and gynaecologists. The cost of a smear
ranges from 100 HKD (ca. 12.8 USD) to 1000 HKD. Liquid-
based cytology is used in about 70% of cases.
HPV DNA testing is widely available. The Hong Kong
College of O&G guidelines recommends that it should be an
adjunct to the cytology screening rather than as a primary
screening test. Women who are negative by both tests can
consider a longer screening interval, for example, 5-6 years.
9.3.2. Ideal Situation in Low- and High-Resource Setting. In
low-resource settings, the ideal situation would be primary
prevention of cervical cancer by a national vaccination
program that provides a vaccine which confers the maximum
protection from cervical cancer (e.g., potential multivalent
vaccine). This would only be feasible if there is significant
price reduction and substantial financial support from
funding agencies, for example, GAVI. Once an HPV vaccine
becomes affordable, the vaccines can be incorporated into
school vaccination programs or into the existing Programs
on Immunization.
Meanwhile, a single-visit VIA followed by cryotherapy
appeared to be the most effective and feasible method. This
should cover women between the ages of 25 and 49. For
menopausal women, where VIA would not be suitable, there
may be a role for HPV testing (e.g., single-visit HPV test +
cryotherapy if HPV positive) but this would require further
evidence.
Hong Kong is a region of high-resource settings, where a
national HPV vaccination program should be implemented
and a school vaccination program for girls aged 11-12 years
appears to be an effective prevention method. Since the exist-
ing vaccine protects against 70% of all cervical cancer cases,
a well-organized national screening program will still be
needed. Liquid-based cytology would allow a computerized
screening system, where the pathologists can concentrate
on the slides most likely to contain abnormalities, as well
as confirmatory (reflex) HPV testing (see Figure 4). In
countries with well-established cytology screening programs,
the role of HPV testing may be towards an ancillary
screening test, for example, for triaging women with ASCUS.
Considerations should be given to developing HPV testing
as a primary screening method, especially where cytology
screening is not well established.
9.3.3. Challenges and Suggestions to Overcome the Obstacles to
Cervical Cancer Prevention in Hong Kong
(a) Economic Challenges. The lack of government funding
represents the major challenge for implementation of effec-
tive vaccination against cervical cancer. However, the relative
high cost of the vaccines also represents an obstacle to be
overcome, even in wealthy places as Hong Kong. There is a
need for multilateral negotiations involving government pro-
curement agencies, health insurance companies, and vaccine
manufacturers to optimize vaccine price and reimbursement
schemes to facilitate vaccine adoption and uptake. Creating
innovative partnerships among health providers to introduce
school-based vaccination programs, and creating attractive
self-financing schemes could contribute to lowering the costs
of vaccination strategies.
(b) Education. Acceptance of HPV vaccination for ado-
lescent girls is still low, and lack of awareness and a
certain degree of anxiety among women regarding HPV and
sexually transmitted infections (STI) are also obstacles to
better disease prevention. Educational campaigns to inform
the public about the benefits of HPV vaccination and
screening are needed. In this respect, educational methods
and materials adapted for different target age groups and
to different socioeconomic layers of the populations should
be developed, for instance, an array of educational booklets,
posters, videos, or cartoons to target younger and older
generations. An active effort to destigmatize the disease
should be made in form of public patient testimony-
based campaigns, supported by public celebrities or opinion
leaders in mass media such as posters, TV, or radio spots, that
may facilitate the task of making vaccination and screening
popular approaches to cervical cancer prevention.
(c) Innovative Screening Strategies. Despite a 63% coverage
of the target population by the cervical screening program,
a substantial subset of the population does not participate
in screening and remains still at risk of inadvertently
progressing to disease. In addition, for women with abnor-
mal screening results, the waiting time for followup by
colposcopy and eventually treatment are too long, reducing
compliance rates to follow up and decreasing the efficiency of
the program. To improve the cervical screening program, one
should increase the number of clinics that can provide smear
taking, especially in more “isolated areas” or outlying islands.
Further, there is a need for continued training of nurses
to take smears and perform colposcopy in order to have
sufficient staffing and shorten the waiting time of follow-up
procedures. One should also intensify “outreach” programs
to inform specific populations to join current screening
programs, and continue efforts to destigmatize the disease
by the mass media (as stated above).
9.4. India
9.4.1. Current Situation in Cervical Cancer Control and
Prevention in India. Cervical cancer is the leading cause of
cancer-related morbidity and mortality in females. In India,
there were an estimated 132,000 cases of cervix cancer in
the year 2002 and 74,100 patients died of the disease [64].
The figures were generated from 18 population-based cancer
registries, most of which are located in the urban areas. While
there has been a gradual decline in cervical cancer incidence,
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the age-standardised rate still remains one of the highest in
Asia Oceania.
Awareness of cervical cancer, as well as of HPV, is low
among the population.
There is no population-based national screening pro-
gram for cervical cancer [65]. Cytology-based screening
continues to be opportunistic with low coverage and has not
reduced the cervical cancer burden.
Recently, screening by VIA has been introduced in some
low-resource settings following the demonstration of its
success in research programs. The HPV DNA test is now
available in the metro cities but is expensive, and awareness
regarding its utility is still not universal.
Both the HPV vaccines have been licensed in India since
2008-2009, and are indicated for prevention among women
between the ages of 10 to 45 years old. The vaccines are
available at most private clinics and medical practitioners,
and the cost of a dose was around USD 60 in the beginning
but already has been reduced to USD 40 per dose.
9.4.2. Ideal Situation in Low- and High-Resources Setting.
India is a country with varied scenarios. The majority of
the population lives in rural areas in low-resource settings.
This area is catered by a well laid out system of primary
health centres and district hospitals, but these suffer from
frequent problems of staffing, lack of resources, and so forth.
About one-fourth of the population in urban areas is affluent
and lives in high-resource settings. Many of these people
have access to insurance and several of them have incomes
that allow them to spend well on healthcare. Thus solutions
need to be adapted according to the region, and within each
region, to the individual setting.
Cervical cytology has been the cornerstone of cervical
cancer prevention programs globally. In developed countries,
widespread cytology-based screening has reduced invasive
cancer cervix rates by 74% [66]. However, Pap smear
has moderate sensitivity, about 50%, although it has high
specificity (86% to 100%) [67]. Successful implementation
requires frequent screening. Such compliance, coverage, and
quality have not been feasible in India.
Overall, the recommended screening guidelines in India
are as follows.
(1) Women 30–55 years old should undergo VIA screen-
ing at least once every 8–10 years as the primary
screening method at rural primary health centres and
subcentres and district hospitals with no Pap smear
capability.
(2) VIA can be used as a screening method even in larger
tertiary level hospital with limited Pap smear facilities
in order to provide wider coverage to the population.
(3) VIA can be used as a triage method to guide biopsies
in case of abnormal Pap smear where colposcopy
facilities are not available, and Pap smear can be used
to triage VIA positive cases. This will decrease the
number of cases that need to be referred for further
management.
(4) Positive or suspicious lesions noted upon screening
should be biopsied/referred immediately.
(5) If the HPV test is available, it can be used as
the primary screening method, with or without
concomitant Pap smear.
(6) The availability of the rapid, affordable HPV test may
open up the possibility of self-sampling for remote
areas as well as for women who are reluctant to get
examined.
(7) Tertiary level hospitals and cancer centres should
be equipped for the management of invasive cancer.
Supportive care facilities should also be available at
these centres.
9.4.3. Challenges and Suggestions to Overcome the Obstacles to
Cervical Cancer Prevention in India
(a) Challenges and Suggestions in Low-Resource Settings
(1) Political barriers
(i) There is a lack of priority for cervical cancer
among public health programs, especially pre-
vention and early detection. Health authorities
and health professionals need to agree on strate-
gies to make optimal use of limited resources.
(ii) Efforts need to be made to incorporate screen-
ing for cervical cancer into the existing primary
health care facilities, in order to minimize
incremental costs for the public.
(iii) Healthcare organizations representing profes-
sionals, patients, or the public in general are
well positioned and empowered to call the
attention of political leaders to the matter:
this can be achieved by efforts to educate the
population by use of mass media (television,
radio, newspaper, campaigns).
(2) Community and individual barriers
(i) Among the public at large, particularly women,
the lack of awareness of cervical cancer as a
health problem is the major obstacle to high
adherence to health programs on prevention,
and compliance with screening. Some culturally
specific attitudes, misconceptions and beliefs,
and shyness of women inhibit discussing dis-
eases of genital tract, and participation in
screening programs. Community leaders need
to be more sensitive and proactive with regard
to women’s health and reproductive health
issues.
(ii) Awareness must be created among the health-
care professionals regarding the magnitude of
the problem and the recent technological devel-
opments in the field. This may be done through
educational and training programs.
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(3) Technical and organizational barriers
(i) These include poorly organized programs cov-
ering the populations at need, lack of screening
registries, weak infrastructure including limited
laboratory facilities, lack of trained manpower,
and lack of quality control for laboratories and
cytology reporting.
(ii) Protocols for screening using the methods
described above should be developed and
guidelines formulated for the target age women
to be screened, frequency of screening, the test
to be used, the reporting of the test, and the
management of screen-positive women.
(iii) The number of facilities should be increased in
proportion to the size of the population.
(4) Cost barriers.
VIA performed by health workers followed by cryother-
apy at the same visit is associated with considerably lower
costs (517 dollars/year of life saved), compared to other
screening strategies [68]. There will be a cost outlay for
providing some basic equipment and materials for tests,
providing recurring supplies, salaries of health workers, and
so forth. HPV testing, even when done only once in a
lifetime, is presently costly (although cost may work out to
be less than repeated screening with Pap).
Efforts need to be made to work through GAVI and
other agencies to procure the HPV vaccine and to make
it available through the Expanded Program on Immuniza-
tion. In general, Indians accept vaccination very positively
and it is expected that there will be good coverage with
the HPV vaccine if it is promoted through a national
program.
(b) Challenges and Suggestions in High-Resource Settings.
Where resources are not a problem, there are certain other
issues such as the lack of disease awareness in the community.
Considerable logistic difficulties in restructuring the existing
screening programs from cytology-based to HPV-based
testing is a major hurdle for change.
(i) Loss to followup is also a problem even in affluent
societies (although situation is better than low-
resource settings). A clear policy by the government
emphasizing the synergistic role of primary and
secondary prevention will go a long way to improve
uptake by this largely affording segment.
(ii) There is an urgent need to develop affordable HPV
testing; HPV genotyping tests suitable for clinical use
must be made widely available, and the healthcare
providers need to be made aware of these technolo-
gies and the advantages they offer over the Pap test.
HPV vaccination must be incorporated into the
national routine vaccination programs.
9.5. The Philippines
9.5.1. Current Situation in Cervical Cancer Control and
Prevention in the Philippines. The Philippines Department
of Health (DOH) has advocated cervical cancer screening,
but less than half (42%) of the 389 Philippine hospitals offer
screening and only 8% have dedicated screening clinics. The
2001/2002 WHO Health Survey reported a dismal 7.7% total
Pap smear coverage of Filipino women aged 18–69 years.
In February 2005, the Philippine DOH established a Cer-
vical Cancer Screening Program to initiate an “organized”
nationwide program that includes sustainable capability
building, training, education, and hiring of health workers
on proper VIA, Pap smear, cytology, colposcopy, and pathol-
ogy. Considering low resources, VIA will be advocated as an
alternative screening method for cervical cancer, especially
in primary and secondary level health care facilities without
Pap smear capability, by the governmental health and welfare
sectors, nongovernment organizations, and professional and
civil societies at the national and local levels. Pap smear
with VIA triage, colposcopy, tissue biopsy, cryosurgery and
surgery treatment, total abdominal hysterectomy (TAH),
and total abdominal hysterectomy with bilateral salpin-
goophorectomy will be available at the secondary healthcare
levels, plus radiotherapy and chemotherapy at the tertiary
level health care facilities.
9.5.2. Ideal Situation in Low- and High-Resource Settings.
The recommended screening guidelines in The Philippines
are the following.
(1) Women 25–55 years old should undergo VIA (with
acetic acid wash) cervical cancer screening at least
once every 5 years in areas with no Pap smear
capability; otherwise Pap smear will be used.
(2) Acetic acid wash (3–5%) should be used as the
primary screening method at the local health units
(rural health units; health centers), district hospitals,
and provincial hospitals with no Pap smear capabil-
ity.
(3) VIA should be used as a triage method before Pap
smear at district, provincial, and regional hospitals
with Pap smear capability.
(4) Positive or suspicious lesions noted upon screening
should be referred immediately.
(5) Referral centers for cervical cancer diagnostic tests
and treatment should be established in tertiary
facilities.
9.5.3. Challenges and Suggestions to Overcome the Obstacles
to Cervical Cancer Prevention in The Philippines. The Philip-
pine Department of Health has not formulated a policy
on HPV vaccination, perhaps stemming from the most
controversial concern that such formal policy could have
a negative impact on the sexual behaviour of the youth.
However, it may be worthwhile to consider the impressions
from the Report Card-HIV Prevention for Girls and Young
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Women (The Philippines) as a framework for a prospective
Philippine HPV Vaccination Program.
Financing is the major obstacle, such as a lack of political
will on the part of the government to allocate the appropriate
budget for the planned programs in cervical cancer screening
and prevention. The lack of organized and highly detailed
networking amongst the lowest levels of health care delivery
may still be a major obstacle. There have been tasks initiated
to begin networking through the CECAP accreditation
program, but the highest level of networking with persistent
and enduring coverage may yet be another task to be really
accomplished.
An integrated national screening registration system that
is linked to a population-based tumor registry could also be
implemented to identify a cohort of vaccinated women who
can be followed up and compared to unvaccinated cervical
cancer cases identified from the tumor registry.
One should increase the involvement of the Philippine
government officials, from the highest to the lowest rank,
in the cervical cancer screening and prevention campaigns,
activities, and continuing awareness. One should present
the government with the challenge to increase funding and
support in the activities and programs of cervical cancer
screening and prevention.
9.6. South Korea
9.6.1. Current Situation in Cervical Cancer Control and
Prevention in South Korea. In the Republic of Korea (further
referred to as South Korea within this paper), urban areas are
developing to high-resource settings, and on the contrary,
rural areas have still insufficient, low-resource-like health
care system. The incidence of cervical cancer has decreased
substantially with the help of nationwide screening system.
According to the Korean Central Cancer Registry, invasive
cervical cancer was the fourth most common malignancy in
Korean women during 1999∼2001 [69], and seventh most
common cancer in 2005. In consideration of age, cervical
cancer is the fourth most common cancer at age of 15–34
year women and fifth most common at age of 35–64 years.
The 5-year survival rate of cervical cancer between 2003 and
2007 is 80.5%, which has raised from 77.5% in 1995 [70].
Although sexual debut in Korean women is around 21 years,
later than reported in other countries [71], the prevalence of
HPV in female students in urban areas is as high as 39% [72].
For primary prevention of cervical cancer, Gardasil and
Cervarix vaccine were approved for use for women in 2007
and 2008, respectively, by Korean Food and Drug Adminis-
tration. A financial support system is not yet established for
HPV preventive vaccination programs in Korea. An average
cost for each vaccination is above 200 US$ in Korea, so young
girls are brought by parents who cover the cost financially.
The vaccination guideline was announced by The Korean
Society of Gynecologic Oncology and Colposcopy in 2007
[73]. Regarding screening, women 21 years and older are
recommended to have a Papanicolaou smear (Pap smear)
annually according to the guideline of Korean Society of
Obstetrics and Gynecology. Also, women aged over 30 years
can have Pap smear done for free with the support of the
National Health Insurance Corporation biannually in Korea.
The Ministry of Health and Welfare reported that 55–
58% of Korean women underwent Pap smear for cervical
cancer program in 2005 [74]. The sensitivity of Pap smear
was shown to range from 55.6% to 83.1%, which was
validated with the results of cervical pathology [75]. In
general, it takes a few days for patients to know the result
of cervical cytology taken at Korean clinics. A HPV DNA
test is not involved in the primary screening system of
cervical cancer and is employed as an ancillary test. In many
private clinics of Korea, cervicography is popularly used as
an adjunct test in the evaluation of women presenting with
abnormal cytology where doctors are lacking experience with
colposcopy. On the other hand, colposcopy is usually utilized
at hospitals associated with medical colleges.
9.6.2. Ideal Situation in Low-Resource Settings. Unfortu-
nately, primary prevention strategies, particularly vaccina-
tion against HPV, are not accessible to women in low-
resource settings. All women 21 years and older, and until the
age of 65 years, should be examined with cervical cytology
by well-trained health provider every year. Cervicography
can be used for women presenting with abnormal cytology
results and the imaging captured by health provider is trans-
mitted to the colposcopists through the internet or mobile
instruments. Women with abnormal results of cervicography
are referred to hospitals where cervical biopsy and optimal
treatment can be performed.
9.6.3. Ideal Situation in High-Resource Settings. The Korean
government is developing the school-based vaccination
program for adolescent girls who are prior to onset of sexual
debut. In general for other vaccines, the cost negotiated
for vaccination is reduced and the programs are supported
entirely by government funds. However, there is to date no
official decision about HPV vaccination programs in Korea.
In high-resource settings, Korean government has no role to
play in supporting the cost of HPV vaccination for young
school girls willing to get and pay for the vaccine.
9.6.4. Challenges and Suggestions to Overcome the Obstacles to
Cervical Cancer Prevention in South Korea. In low-resource
settings, most women are not regularly screened for cervical
cancer, where health care service is not available to them,
and health information is not sufficiently provided. There are
few health providers able to interpret cervical cytology and
provide infrastructures to store and transport the samples to
laboratory safely.
(i) In low-resource settings, the most important factor
to decrease the incidence of cervical cancer is likely to
raise the awareness of HPV and cervical cancer, and
to let women have a regular check up.
(ii) A lack of awareness of cervical cancer should be
overcome by a nationwide educational program. The
information about cervical cancer can be delivered
through multimedia tools such as advertisement on
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television, radio, newspapers, internet, and mobile
instruments. Also, mailing service from The Ministry
of Health and Welfare should be started concerning
the time of examination and result of cervical
cytology. Regular mailing services and advertisement
can compensate for loss of followup and poor
compliance. Health providers are well trained and
dispatched to the areas with low-resource settings.
In high-resource settings, cervical cytology should be done
free for all women annually under the coordination and
supervision of government. Public and private health insur-
ance can be considered to cover the vaccination program.
9.7. Singapore
9.7.1. Current Situation in Cervical Cancer Control and
Prevention in Singapore. Cervical cancer has been a major
cancer worldwide for a long time. Countries that have suc-
cessfully reduced its incidence and mortality have relied on a
meticulous secondary prevention by Pap smear screening in
the last 50 years. Countries which failed, or could not afford
to implement a cervical screening program, continue to have
a high incidence of cervical cancers.
The life expectancy of cancer patients in Singapore has
increased in recent decades due to better diagnostic and
screening tools as well as better treatment modalities. A
steady improvement in overall long-term cancer survival was
observed, and this upward trend in survival with a favourable
prognosis includes cervical cancers [76].
While effective, screening and treating precancers is a
very costly program to prevent cervical cancer. Unless it is
maintained year after year, and indefinitely, the incidence of
cervical cancer will rise again soon as the effort wanes. Hence,
preventing cervical cancer will remain as a predominant
health concern for as long as its preventive effort is not
targeted at the principal etiologic factor and implementing
primary prevention strategies.
Prophylactic HPV vaccines have been licensed in Sin-
gapore; however, routine comprehensive public vaccination
program for adolescent girls has yet to be adopted by the gov-
ernmental agency, despite an affirmative recommendation by
medical professional bodies [77].
9.7.2. Ideal Situation in Singapore. Persistent cervical infec-
tion with high-risk oncogenic HPVs is now known to be
essential etiologic factor of cervical cancers. Therefore, herein
is the opportunity for the disease to be effectively controlled
worldwide in a decisive manner, like how we have done so
for small pox, without the need to maintain a secondary
prevention system indefinitely. Effective vaccinations against
most, if not all, high-risk oncogenic HPV infections must
therefore be the key to potential eradication of cervical
cancers.
The effectiveness of vaccination in preventing and con-
trolling life threatening infections has been well proven in
many other viral diseases like small pox, rubella, mumps,
measles, poliomyelitis, Hepatitis-B, and so forth. Therefore,
in a world where HPV vaccinations are given to successive
cohorts of HPV-naı¨ve women for a full generation, we will
definitely see a progressive decline of cervical precancers and
invasive cancers within a span of 30 to 50 years. What then is
stopping the world from doing so?
9.7.3. Challenges and Suggestions to Overcome the Obstacles
to Cervical Cancer Prevention in Singapore. Several key
factors obstruct the world from adopting population HPV
vaccinations to control cervical cancers effectively, namely.
(1) The expensive HPV vaccines that countries with large
populations and with the higher cervical cancer rates
could ill-afford.
(2) The imperfect HPV vaccines which target only 2
main oncogenic strains, albeit that they are respon-
sible for a good majority of cervical cancers, but still
not 100%.
(3) The absence of governmental-sponsored cervical
cancer preventive programs in many countries in the
first place.
(4) The fact that cervical cancer, in a major proportion,
is a disease of the poorer communities, where the
monthly wage of an individual could even be less than
the cost of a single dose of HPV vaccine.
Most of these obstacles are fundamentally difficult to over-
come without transcending sociopolitical issues that may be
highly sensitive in nature.
Firstly, there is no doubt that the solution for widespread
adoption of population HPV vaccinations is that the costs
of the HPV vaccines have to be very much lower than what
it is today. Historically, this was the case for Hepatitis B
vaccination, which was not adopted by public vaccination
programs and did not become widespread until the cost
of the vaccine was much reduced. Secondly, a worldwide
endorsement of HPV vaccinations against cervical cancer
would be most effective in reminding governmental interest,
preferably by a leading health agency such as the World
Health Organization. Thirdly, HPV vaccines development
programs need to be expedited to produce newer generations
of HPV vaccines which are more effective. Fourthly, going
against the grain of current belief, it is possible that the
availability of an affordable and quick cervical HPV test kit
that determines a woman’s cervicovaginal status of vaccine-
types HPV infection can positively impact on a woman’s urge
to go for HPV vaccinations. People who have been found to
be at risk for hepatitis B, as revealed by raising suboptimal
levels of Hepatitis B antibodies, would usually agree to have
the vaccination, almost instantaneously. Likewise, women
who are tested negative for HPV-16 and 18 may gladly see
the need and the benefits of having an HPV vaccination.
The current irony of HPV vaccination is that countries
which have adopted population HPV vaccination programs
are countries which have an effective cervical screening
program and a low incidence of cervical cancers in the first
instance. These countries not only have had put cervical
cancer prevention as a priority, but have now refocused
their preventive effort to target the principal etiologic factor.
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This is so that one day they may be able to do away with
the costly cervical screening program, when their incidences
of cervical cancers become low, making population-based
cervical screening programs not cost-effective to sustain. For
the rest of the countries that have not even implemented an
effective cervical screening program, perhaps with limited
resources they may channel them to HPV vaccinations
directly, hence preventing cervical cancers more effectively at
the primary level.
9.8. Taiwan
9.8.1. Current Situation in Cervical Cancer Control and
Prevention in Taiwan. The National Cervical Cancer Screen-
ing Program of Taiwan, launched in 1995, provides yearly
Pap smear for women 30 years or older. The screening
program includes an informative system, a quality control
and monitoring system and an education system that covers
public health nurses, physicians, cytotechnicians, and cytol-
ogists. Several factors support the success of this program:
(1) well-established public health infrastructure, (2) highly
efficient National Health Insurance Program covering 99%
of the population, and (3) highly resourced gynecological
and oncology services. The registered 3-year screening rate
reached 53% coverage in 2000. From 2010, a self-sampling
HPV test was provided for women who are reluctant to be
screened by others. The national health statistics data before
1995 [78] and a decade after the launch of the program
(2006-2007) [79], has showed a steady decline in the
incidence rate of cervical cancer from 25.0 to 13.0/100,000,
and the mortality rate dropped from 13.8 to 5.8/100,000.
In fact, the mortality rate had been improving slowly and
steadily before the launch of the program, mainly attributed
to the continuous advancement of therapeutic care. In 2009,
the overall survival rate of cervical cancer in Taiwan was 74%
[80].
Several modeling studies have indicated that HPV vac-
cination, alone or when added to the current screening
program, is cost effective in Taiwan [81, 82]. However,
the consensus of mass vaccination as a major tool in
cervical cancer prevention has not been completely reached.
Population-based vaccination program has been running in
one county and scheduled in another. A national policy of
vaccinating women of low socio-economic status has been
set, but not carried out yet.
9.8.2. Ideal Situation in Current Resource Setting. Although
successful, the cost of cervical cancer screening is still expen-
sive and can be much reduced by adopting new screening
tools and strategies. The strategy of primary screening
with HPV test with Pap smear-triage of positive cases has
found sound support on both safety and effectiveness in a
nationwide [83] and a large-scale regional cohort studies
in Taiwan [84]. With the scenario that yearly Pap smear
being applied only to women with persistent HPV infection,
identified by HPV, screening every five years and a repeat test
one year later for positive women, only 3% of women would
require yearly Pap smear, and another 5% may require one
smear in five years. The direct and indirect costs can be cut to
35% and 23% of the current levels, respectively. Meanwhile,
gene methylation test has been proved to be as sensitive as,
and more specific than, HPV test in detecting CIN3 or more
severe lesions in two hospital-based case-control studies in
Taiwan [85, 86]. In a nationwide multicenter cohort study,
the methylation test was more effective than HPV test in
triage of equivocal Pap smear results [87]. This new test holds
great promise for a cytology-free, laboratory-based screening
of cervical cancer and warrants further population-based
studies.
9.8.3. Challenges and Suggestions to Overcome the Obstacles
to Cervical Cancer Prevention in Taiwan. The procedure of
cervical sampling remains to be the major psychological
obstacle to women’s willingness to accept cervical cancer
screening in Taiwan [88]. Ideological issues such as sexu-
ality and discrimination also exist, preventing nationwide
vaccination for cervical cancer. Furthermore, the emerging
success of current Pap screening program may wean the
demand of the new HPV-orientated prevention tools in
policy making.
With the adoption of primary HPV-oriented cytology
screening the screening interval can be lengthened and at
five-year interval, the cost can be largely reduced. The saved
resources can be shifted to an HPV vaccination program, in
a gradual and population-stratified base. The new screening
strategy will require consensus and guidelines among health
professionals, properly priced screening products, quality-
certified central laboratories, and most importantly, correct
and convincing health messages to the public.
9.9. Thailand
9.9.1. Current Situation in Cervical Cancer Prevention and
Control in Thailand. Thailand has long recognized the
problem of cervical cancer with its highest incidence and
mortality among the female cancers, with an incidence rate
of 24.5 (ASR) and mortality of 12.8 per 100.000 women (cf.
Globocan http://www.iarc.fr/). Many campaigns before the
year 2004 for cervical cancer screening with Pap smear were
not successful due to the nonsystematic approach and mostly
being an opportunistic program. Screening mostly was done
on the same group of women in the population and hence
resulting in low coverage.
In the years 2004–2009, Thailand has established the
National Screening Program using conventional Pap smear
as the main method and VIA for areas of low resources. The
Pap smear was widely used while the VIA was performed in
only 9 out of 76 provinces. The initial goal was to have its
coverage of 50% or more of the targeted population, women
aged 35–60 years, at five-year interval. As a matter of fact,
at the end of the first five-year period program which was
in 2009, the organized program did not achieve its targeted
coverage with only about 25% participation. Problem of data
input may be also one of the reasons for the reported low
coverage. Experience and lessons from the past five years
have prompted us to reform and improve our strategy for
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the next five years period program, from 2010 to 2014, using
the Pap smear all over the country, in conjunction with
VIA in some areas. The program has extended the age of
screening from age 30 to 60 years with a five-year interval.
Funding comes from the National Health Security Office
in collaboration with the management of National Cancer
Institute of Thailand for data processing covering the whole
country except Bangkok Metropolitan area.
9.9.2. Ideal Situation in Low- and High-Resource Settings.
Primary prevention: HPV vaccines with an affordable cost
for national Expanded Program on Immunization should be
the ideal primary prevention strategy for young generations.
A multivalent vaccine or based on the L2 capsid protein of
the virus, to be administered in oral formulation (if it is
possible) and temperature stable would be privileged.
Secondary prevention: Low-cost HPV test, especially
with the possibility of self-collection, and equivalent sensitiv-
ity and specificity to the currently standard test, will be ideal
for screening both low- and high-resource settings. Using
the Pap smear as the triage and making the colposcopy with
treatment of precancerous lesions available will also be an
important success factor.
9.9.3. Challenges and Suggestions to Overcome the Obstacles
in Cervical Cancer Prevention in Thailand. The difference
of culture, educational, and socio-economical status has led
some women to feel shy for pelvic examination. Vaccination
would offer an alternative to overcome these cultural aspects.
However, the high cost of HPV tests and vaccines has
prevented these ideal methods from being widely used in
Thailand. Even though some can afford for HPV testing,
there is some fear of detecting the disease by a positive
screening result, which is also a cause of avoiding the
screening.
Misunderstanding of the principles of HPV vaccines
immunization is also a cause of low vaccination adoption
and coverage. Negotiations between the government and the
pharmaceutical companies to provide affordable HPV tests
and HPV vaccines are desirable.
The choice of using Pap smear or VIA in some areas is
a dilemma. The problem of data entry from all the health
service centers, with the heavy workload each center is facing,
means submission of data is becoming a burden.
(i) The referral and followup system for those with
abnormal result should be improved.
(ii) It is encouraged that the data on followup and cases
be provided to the center for evaluation and audit.
(iii) There is a need to increase the quality of Pap smears,
the number, and skills of health care personnel and
cytology screeners, and for results of the test to reach
the target population for followup, when applicable.
(iv) The quality of colposcopy and treatment of precan-
cerous lesions should also improve.
(v) VIA should only be the method of choice in areas
where Pap smear is not available, to avoid the
confusion of the women and health care providers.
Only a comprehensive approach with coordination between
the government sectors, academic and professional societies,
private and charity organizations, and so forth, combined
with a sustainable policy and fully support to the prevention
and control of cervical cancer, will have a significant result
within a short period.
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